en · de · es · fr · pt
tb-500-notes.peptides4800.com › Guide › Tb-500 Identity And Chemical Background — Deep Dive

Tb-500 Identity And Chemical Background — Deep Dive

By Editorial Desk · published 2025-12-13 · last reviewed 2026-01-05 · Guide

lyophilised powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-01-05. Where a claim depends on a specific study, the study is described rather than over-claimed.

TB-500 Identity and Chemical Background

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

Handling, Storage, and Analysis

Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.

Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.

Tb-500 at a glance

PropertyValueNotes
Physical formLyophilised powderSealed vial; reconstituted before laboratory use
AppearanceWhite to off-white solidVisual descriptor used on certificates of analysis
Solubility classWater-solubleDissolves in water and aqueous buffers
Reported mass, fragmentNear 889 DaValue depends on the stated sequence
Reported mass, parent proteinNear 4963 Da43-residue thymosin beta-4

TB-500 Background and Identity

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

Related pages on this site

Identification and Molecular Background

TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.

Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.

Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.

Storage and Analytical Verification

Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.

Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.

Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.

Background from the literature

=== Symptoms === Pain Paresthesia Spasticity, Hypertonia Muscular Dysfunction or Weakness Radiculopathy Although Tarlov Cysts can develop anywhere along the spine, they are most commonly symptomatic in the sacrum. Women are more likely to exhibit symptoms. They can also appear in clusters or bilaterally along the spine, thus symptoms can be unilateral, bilateral, or with symptoms more dominant on one side. The cases of reported symptomatic Tarlov cysts ranges from 15% to 30% of the overall reported Tarlov cyst cases, depending on the source of literature. Nevertheless, these cysts are important clinical entities because of their tendency to increase in size over time, potentially causing complications and eroding the surrounding bone tissue.

== Risks == The risks are similar to other intraocular procedures, but additionally include graft rejection (lifelong), detachment or displacement of lamellar transplants and primary graft failure. Use of immunosuppressants including cyclosporine A, tacrolimus, mycophenolate mofetil, sirolimus, and leflunomide to prevent graft rejection is increasing but there is insufficient evidence to ascertain which immunosuppressant is better. In a Cochrane review which included low to moderate quality evidence, adverse effects were found to be common with systemic mycophenolate mofetil, but less common with topical cyclosporine A or tacrolimus. There is also a risk of infection. Since the cornea has no blood vessels (it takes its nutrients from the aqueous humor) it heals much more slowly than a cut on the skin. While the wound is healing, it is possible that it might become infected by various microorganisms. This risk is minimized by antibiotic prophylaxis (using antibiotic eyedrops, even when no infection exists). There is a risk of cornea rejection, which occurs in about 10% of cases. Graft failure can occur at any time after the cornea has been transplanted, even years or decades later. The causes can vary, though it is usually due to new injury or illness. Treatment can be either medical or surgical, depending on the individual case. An early, technical cause of failure may be an excessively tight stitch cheesewiring through the sclera. Infectious disease transmission through corneal transplantation is exceedingly rare.

=== Tobacco === Polonium-210 in tobacco contributes to many of the cases of lung cancer worldwide. Most of this polonium is derived from lead-210 deposited on tobacco leaves from the atmosphere; the lead-210 is a product of radon-222 gas, much of which appears to originate from the decay of radium-226 from fertilizers applied to the tobacco soils. The presence of polonium in tobacco smoke has been known since the early 1960s. Some of the world's biggest tobacco firms researched ways to remove the substance—to no avail—over a 40-year period. The results were never published.

Sources: en.wikipedia.org

Further detail

Tendons are not elastic and are even less stretchy. Tendons are categorized as a connective tissue. Connective tissue supports, surrounds, and binds the muscle fibres. They contain both elastic and non-elastic tissue.

=== Outcomes === Treatment with docetaxel increases survival time in people with certain types of cancer. While some clinical trials show median survival times to be increased by approximately only three months, the range of survival time is large. Many people survive beyond five years with treatment from docetaxel, however it is difficult to attribute these findings directly to treatment with docetaxel. Improved median survival time and response indicates that docetaxel slows metastatic cancer progression and can lead to disease-free survival. Conjunctive treatment of prednisone with docetaxel has been shown to lead to improved survival rate as well as improved quality of life and reduction of pain compared with treatments with mitoxantrone. As well as inhibiting mitosis, the presence of docetaxel has been found to lead to the phosphorylation of the oncoprotein bcl-2, which leads to apoptosis of cancer cells that had previously blocked the apoptotic inducing mechanism, leading to tumour regression. Enhanced effects of radiation therapy when combined with docetaxel has been observed in mice. Docetaxel has also been found to have greater cellular uptake and is retained longer intracellularly than paclitaxel allowing docetaxel treatment to be effective with a smaller dose, leading to fewer and less severe adverse effects.

Hooker Hamersley (1865), heir, lawyer, and poet; former president of the Knickerbocker Club Shipley Jones (1868), banker and clubman William Bayard Cutting (1869), financier, philanthropist, namesake of the Bayard Cutting Arboretum State Park Robert Fulton Cutting (1871), financier George Beach de Forest Jr. (1871), capitalist, bibliophile, and art collector Stuyvesant Fish (1871), president of the Illinois Central Railroad James Montaudevert Waterbury Sr. (1873), industrialist, co-founder of the New York Yacht Club Isaac Newton Seligman (1876), heir to investment bank J. & W. Seligman & Co. T. J. Oakley Rhinelander (1878), heir and real estate developer who owned the Schönburg castle in Germany William Fellowes Morgan Sr. (1880), businessman, philanthropist George Henry Warren II (1880), stockbroker and real estate developer who co-founded the Metropolitan Opera and Real Estate Company Eugene Higgins (1882), heir and philanthropist Lewis Morris Rutherfurd Jr. (1882), socialite and sportsman Marshall Orme Wilson (1882), banker and socialite, son-in-law of William Backhouse Astor Jr. George M. La Monte* (1884), chairman of Prudential Financial 1925–1927 Joseph P. Knapp* (1884), businessman, philanthropist, founder of Ducks Unlimited Temple Bowdoin (1885), former executive of J.P. Morgan & Co. Benjamin Guggenheim* (1887), businessman, son of Meyer Guggenheim and member of the Guggenheim family Richard Thornton Wilson Jr.

The old wood effect or old wood problem is a pitfall that occurs in the archaeological technique of radiocarbon dating. A sample will provide misleading or confusing results if materials of different ages are deposited in the same context. Stratification is not always clear-cut in practice. In the case of dating megalithic tombs, indirect evidence for the age of the tomb must always be obtained, because stone (or the time of moving a stone) cannot be dated. When a number of objects are recovered from one deposit, the terminus post quem is based on the dating from the 'youngest' find. Even though other items in the same stratum indicate earlier dates, they may have been deposited at the same time. The deposit must be as young, or younger than the youngest object it contains. Thus excavators look to post holes, pits, or find spots under the orthostats for clues to construction dates. The possibility that something (organic) was already in situ must always be considered, especially if the results appear suspiciously early. The old wood problem can appear in marine archaeology. Researchers need to check if stumps from a Mesolithic or Palaeolithic submerged forest are to be found in the area. (If they do, the possibility of one sticking up through, e. g., a shipwreck and giving misleading dates must be considered.) Organic samples which are not derived from the same part of an organism, may show dating variations which blur and obscure the interpretation being attempted.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.

Why do product listings show different sequences?

Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.

What is the reported molecular mass?

The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.

How is the material stored?

The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.

Network